Wang Minghua, Liu Junli, Wang Fan, Li Qing, Zhang Jian, Ji Sibei, Li Shaomin, Lu Chengbiao, Zhao Jianhua
Henan Joint International Research Laboratory of Neurorestoratology for Senile Dementia, Henan Key Laboratory of Neurorestoratology, Neurology, First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Imaging Department, First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Front Aging Neurosci. 2023 Jun 22;15:1221548. doi: 10.3389/fnagi.2023.1221548. eCollection 2023.
The study investigated the correlation and predictive value between the severity of cerebral microbleeds (CMBs) and the level of serum High Mobility Group Protein B1 (HMGB1) and the occurrence of cognitive impairment in patients with cerebral small vessel disease (CSVD).
A total of 139 patients with CSVD admitted to the Department of Neurology of the First Affiliated Hospital of Xinxiang Medical University from December 2020 to December 2022 were selected as study subjects. The Montreal Cognitive Assessment (MoCA) scale was used to assess the cognitive function and was divided into the cognitive impairment group and the cognitive normal group. Magnetic Resonance Imaging (MRI) and Susceptibility Weighted Imaging (SWI) were used to screen and assess the severity of CMBs. Serum HMGB1 levels of CSVD patients were measured by enzyme linked immunosorbent assay (ELISA). Multivariable logistic regression analysis was used to explore risk factors for cognitive impairment and CMBs. correlation analysis was used to investigate the correlation between HMGB1 and cognitive function. Receiver Operating Characteristics (ROC) curves were used to assess the predictive value of HMGB1 for the occurrence of cognitive impairment in patients with CMBs.
High Mobility Group Protein B1, uric acid (UA), glycosylated hemoglobin (HbA1c), CMBs, lacunar cerebral infarction (LI), years of education, and history of hypertension were risk factors for cognitive impairment ( < 0.05); HMGB1 was significantly and negatively associated with total MoCA score, visuospatial/executive ability, and delayed recall ability ( < 0.05). HMGB1 was significantly and positively correlated with the number of CMBs ( < 0.05). The area under the ROC curve for HMGB1 predicting cognitive impairment in patients with CMBs was 0.807 ( < 0.001).
Serum HMGB1 levels are associated with the development of cognitive impairment in CSVD patients, and serum HMGB1 levels have a high predictive value for the development of cognitive impairment in CSVD patients with combined CMBs, which can be used for early clinical identification and intervention of vascular cognitive impairment.
本研究探讨脑小血管病（CSVD）患者脑微出血（CMB）严重程度与血清高迁移率族蛋白B1（HMGB1）水平及认知障碍发生之间的相关性和预测价值。
选取2020年12月至2022年12月在新乡医学院第一附属医院神经内科住院的139例CSVD患者作为研究对象。采用蒙特利尔认知评估（MoCA）量表评估认知功能，分为认知障碍组和认知正常组。采用磁共振成像（MRI）和磁敏感加权成像（SWI）筛查并评估CMB的严重程度。采用酶联免疫吸附测定（ELISA）法检测CSVD患者血清HMGB1水平。采用多变量logistic回归分析探讨认知障碍和CMB的危险因素。采用相关性分析研究HMGB1与认知功能之间的相关性。采用受试者工作特征（ROC）曲线评估HMGB1对CMB患者认知障碍发生的预测价值。
高迁移率族蛋白B1、尿酸（UA）、糖化血红蛋白（HbA1c）、CMB、腔隙性脑梗死（LI）、受教育年限和高血压病史是认知障碍的危险因素（<0.05）；HMGB1与MoCA总分、视觉空间/执行能力及延迟回忆能力显著负相关（<0.05）。HMGB1与CMB数量显著正相关（<0.05）。HMGB1预测CMB患者认知障碍的ROC曲线下面积为0.807（<0.001）。
血清HMGB1水平与CSVD患者认知障碍的发生有关，血清HMGB1水平对合并CMB的CSVD患者认知障碍的发生具有较高的预测价值，可用于血管性认知障碍的早期临床识别和干预。
